MedTrace Logo

Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke

NCT03296618 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-10-05

No results posted yet for this study

Summary

The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.

Conditions

  • Ischemic Motor Stroke, Chronic

Interventions

DRUG

NSI-566

Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.

Sponsors & Collaborators

  • Suzhou Neuralstem Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Xu Ruxiang, M.D · BaYi Brain Hospital, Army General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296618 on ClinicalTrials.gov